Microglial activation, white matter tract damage and disability in multiple sclerosisCitation formats

  • External authors:
  • Eero Rissanen
  • Jouni Tuisku
  • Tero Vahlberg
  • Marcus Sucksdorff
  • Teemu Paavilainen
  • Riitta Parkkola
  • Johanna Rokka
  • Juha O Rinne
  • Laura Airas

Standard

Microglial activation, white matter tract damage and disability in multiple sclerosis. / Rissanen, Eero; Tuisku, Jouni; Vahlberg, Tero; Sucksdorff, Marcus; Paavilainen, Teemu; Parkkola, Riitta; Rokka, Johanna; Gerhard, Detlef Alexander; Hinz, Rainer; Talbot, Peter; Rinne, Juha O; Airas, Laura.

In: Neurology: Neuroimmunology & Neuroinflammation, Vol. 5, No. 3, 06.03.2018.

Research output: Contribution to journalArticlepeer-review

Harvard

Rissanen, E, Tuisku, J, Vahlberg, T, Sucksdorff, M, Paavilainen, T, Parkkola, R, Rokka, J, Gerhard, DA, Hinz, R, Talbot, P, Rinne, JO & Airas, L 2018, 'Microglial activation, white matter tract damage and disability in multiple sclerosis', Neurology: Neuroimmunology & Neuroinflammation, vol. 5, no. 3. https://doi.org/10.1212/NXI.0000000000000443

APA

Rissanen, E., Tuisku, J., Vahlberg, T., Sucksdorff, M., Paavilainen, T., Parkkola, R., Rokka, J., Gerhard, D. A., Hinz, R., Talbot, P., Rinne, J. O., & Airas, L. (2018). Microglial activation, white matter tract damage and disability in multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 5(3). https://doi.org/10.1212/NXI.0000000000000443

Vancouver

Rissanen E, Tuisku J, Vahlberg T, Sucksdorff M, Paavilainen T, Parkkola R et al. Microglial activation, white matter tract damage and disability in multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation. 2018 Mar 6;5(3). https://doi.org/10.1212/NXI.0000000000000443

Author

Rissanen, Eero ; Tuisku, Jouni ; Vahlberg, Tero ; Sucksdorff, Marcus ; Paavilainen, Teemu ; Parkkola, Riitta ; Rokka, Johanna ; Gerhard, Detlef Alexander ; Hinz, Rainer ; Talbot, Peter ; Rinne, Juha O ; Airas, Laura. / Microglial activation, white matter tract damage and disability in multiple sclerosis. In: Neurology: Neuroimmunology & Neuroinflammation. 2018 ; Vol. 5, No. 3.

Bibtex

@article{5ebd8d6174fa402aa7b6429796940d84,
title = "Microglial activation, white matter tract damage and disability in multiple sclerosis",
abstract = "Objective: To investigate the relationship of in vivo microglial activation to clinical and MRI parameters in multiple sclerosis.Methods: Secondary progressive (n = 10) or relapsing (n = 10) multiple sclerosis patients, and age matched healthy controls (n = 17) were studied. Microglial activation was measured using PET and [11C](R)-PK11195 radioligand. Clinical assessment, and structural and quantitative MRI including diffusion tensor imaging were performed for comparison.Results: [11C](R)-PK11195 binding was significantly higher in the normal appearing white matter of secondary progressive vs. relapsing multiple sclerosis patients and healthy controls, in the thalami of secondary progressive patients vs. controls, and in the perilesional area among the progressive compared to relapsing patients. Higher binding in the normal appearing white matter was associated with higher clinical disability and with reduced white matter structural integrity, as shown by lower fractional anisotropy, higher mean diffusivity and with increased white matter lesion load. Increasing age contributed to higher microglial activation in the normal appearing white matter among multiple sclerosis patients, but not in healthy controls.Conclusions: PET can be used to quantitate microglial activation, which associates with multiple sclerosis progression. This study demonstrates that increased microglial activity in the normal appearing white matter correlates closely with impaired white matter structural integrity, and thus offers one rational pathological correlate to diffusion tensor imaging parameters. ",
author = "Eero Rissanen and Jouni Tuisku and Tero Vahlberg and Marcus Sucksdorff and Teemu Paavilainen and Riitta Parkkola and Johanna Rokka and Gerhard, {Detlef Alexander} and Rainer Hinz and Peter Talbot and Rinne, {Juha O} and Laura Airas",
year = "2018",
month = mar,
day = "6",
doi = "10.1212/NXI.0000000000000443",
language = "English",
volume = "5",
journal = "Neurology: Neuroimmunology & Neuroinflammation",
issn = "2332-7812",
publisher = "Wolters Kluwer Health",
number = "3",

}

RIS

TY - JOUR

T1 - Microglial activation, white matter tract damage and disability in multiple sclerosis

AU - Rissanen, Eero

AU - Tuisku, Jouni

AU - Vahlberg, Tero

AU - Sucksdorff, Marcus

AU - Paavilainen, Teemu

AU - Parkkola, Riitta

AU - Rokka, Johanna

AU - Gerhard, Detlef Alexander

AU - Hinz, Rainer

AU - Talbot, Peter

AU - Rinne, Juha O

AU - Airas, Laura

PY - 2018/3/6

Y1 - 2018/3/6

N2 - Objective: To investigate the relationship of in vivo microglial activation to clinical and MRI parameters in multiple sclerosis.Methods: Secondary progressive (n = 10) or relapsing (n = 10) multiple sclerosis patients, and age matched healthy controls (n = 17) were studied. Microglial activation was measured using PET and [11C](R)-PK11195 radioligand. Clinical assessment, and structural and quantitative MRI including diffusion tensor imaging were performed for comparison.Results: [11C](R)-PK11195 binding was significantly higher in the normal appearing white matter of secondary progressive vs. relapsing multiple sclerosis patients and healthy controls, in the thalami of secondary progressive patients vs. controls, and in the perilesional area among the progressive compared to relapsing patients. Higher binding in the normal appearing white matter was associated with higher clinical disability and with reduced white matter structural integrity, as shown by lower fractional anisotropy, higher mean diffusivity and with increased white matter lesion load. Increasing age contributed to higher microglial activation in the normal appearing white matter among multiple sclerosis patients, but not in healthy controls.Conclusions: PET can be used to quantitate microglial activation, which associates with multiple sclerosis progression. This study demonstrates that increased microglial activity in the normal appearing white matter correlates closely with impaired white matter structural integrity, and thus offers one rational pathological correlate to diffusion tensor imaging parameters.

AB - Objective: To investigate the relationship of in vivo microglial activation to clinical and MRI parameters in multiple sclerosis.Methods: Secondary progressive (n = 10) or relapsing (n = 10) multiple sclerosis patients, and age matched healthy controls (n = 17) were studied. Microglial activation was measured using PET and [11C](R)-PK11195 radioligand. Clinical assessment, and structural and quantitative MRI including diffusion tensor imaging were performed for comparison.Results: [11C](R)-PK11195 binding was significantly higher in the normal appearing white matter of secondary progressive vs. relapsing multiple sclerosis patients and healthy controls, in the thalami of secondary progressive patients vs. controls, and in the perilesional area among the progressive compared to relapsing patients. Higher binding in the normal appearing white matter was associated with higher clinical disability and with reduced white matter structural integrity, as shown by lower fractional anisotropy, higher mean diffusivity and with increased white matter lesion load. Increasing age contributed to higher microglial activation in the normal appearing white matter among multiple sclerosis patients, but not in healthy controls.Conclusions: PET can be used to quantitate microglial activation, which associates with multiple sclerosis progression. This study demonstrates that increased microglial activity in the normal appearing white matter correlates closely with impaired white matter structural integrity, and thus offers one rational pathological correlate to diffusion tensor imaging parameters.

U2 - 10.1212/NXI.0000000000000443

DO - 10.1212/NXI.0000000000000443

M3 - Article

VL - 5

JO - Neurology: Neuroimmunology & Neuroinflammation

JF - Neurology: Neuroimmunology & Neuroinflammation

SN - 2332-7812

IS - 3

ER -